好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2010 Annual Meeting | Clinical Issues in Multiple Sclerosis

Friday 04/16/10
09:00 AM - 12:45 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
AM Half-Day Course
Brian G. Weinshenker, MD, FAAN
Participants should appreciate the following controversies: whether MS can be diagnosed in a presymptomatic state; whether vitamin D deficiency is relevant to susceptibility to MS; whether immunotherapy is appropriate for patients with progressive forms of MS; the risks of mitoxantrone and whether they are justified; and whether fatigue is best managed with stimulant drugs or alternative approaches. Participants should have enhanced understanding of diagnostic and therapeutic strategies for common and unusual CNS demyelinating diseases.
No CME available
Patient Care & Procedural Skills, Medical Knowledge
Other, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist
Case-based, Didactic, Interactive, Audience Participation
Event Timeline
09:00 AM - 09:15 AM Debate: Argument For: Resolved That MS Can Be Reliably Diagnosed in Presymptomatic Individuals
Brian G. Weinshenker, MD, FAAN
09:15 AM - 09:30 AM Debate: Argument Against: Resolved That MS Can Be Reliably Diagnosed in Presymptomatic Individuals
Paul W. O'Connor, MD
09:30 AM - 09:50 AM Rebuttals and Summary
09:50 AM - 10:05 AM Management of Fatigue in MS: Should We Use Stimulants or Alternative Treatments First?
Dean M. Wingerchuk, MD, FAAN
10:05 AM - 10:20 AM Debate: Argument For: Resolved That Immunotherapy Is Not Beneficial for Patients With Progressive Forms of MS and It Is Inappropriate to Prescribe Such Therapy
Alasdair Coles, MD, PhD
10:20 AM - 10:35 AM Debate: Argument Against: Resolved That Immunotherapy Is Not Beneficial for Patients With Progressive Forms of MS and It Is Inappropriate to Prescribe Such Therapy
Dean M. Wingerchuk, MD, FAAN
10:35 AM - 10:55 AM Rebuttals and Summary
10:55 AM - 11:10 AM Break
11:10 AM - 11:25 AM Role of Vitamin D in MS Causation/Pathogenesis: Important Etiological Factor or Oversimplified Explanation of the Latitudinal Gradient?
Paul W. O'Connor, MD
11:25 AM - 11:40 AM Risks of Mitoxantrone: Are the Risks of Leukemia and Cardiotoxicity Justified?
Alasdair Coles, MD, PhD
11:40 AM - 12:45 PM Interactive Case Discussions: Diagnostic Difficulties, Early Management Controversies, and Treatment of Refractory Cases
Brian G. Weinshenker, MD, FAAN, Dean M. Wingerchuk, MD, FAAN
Faculty Disclosures
Brian G. Weinshenker, MD, FAAN Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Dean M. Wingerchuk, MD, FAAN Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Paul W. O'Connor, MD No disclosure on file
Alasdair Coles, MD, PhD Dr. Coles has nothing to disclose.